Prof. Dr. ir. Jonathan A. Lal
Department of Molecular & Cellular Engineering
B.Tech.; M.Sc.; PDEng.; Ph.D
|Area of Specialization
Biotechnology, Public Health Genomics, Bioproduct Design
Dr. ir. Lal is working as Director (Innovation, Projects & Consultancy), Dean (Jacob Institute of Biotechnology & Bioengineering) and Professor (Biotechnology), all at Sam Higginbottom University of Agriculture, Technology & Sciences, India.
Previously, he worked in the Netherlands as the CEO - ptTheragnostic BV, Director - Health Innovation Ventures BV & prior to that CSO - ptTheragnostic BV. He was also a researcher in the department of Radiotherapy, Maastricht University & CSO - Maastro Clinic, both in the Netherlands.
Prior to this, he worked as a researcher at the Institute for Public Health Genomics at Maastricht University, the Netherlands. During this time he was also the project manager of the ERA-NET ERAfrica project 'InnXchange'.
Before that, during his time at Maastricht University, he had also worked as the project manager of the EU DG SANCO 'Public Health Genomics European Network' and had also worked as a B-Team member for the EU pilot flagship project IT Future of Medicine. In addition, he had briefly worked as a research advisor for the European Alliance for Personalised Medicine (EUAPM).
Previous to this, he worked as a Bioproduct Designer at Delft University of Technology, the Netherlands.
He has experience with entrepreneurship, valorization, management, financial administration, negotiations, contracts, spin-offs, acquisitions, business development, health policy, best practice guidelines, personalized medicine, public health genomics, biotech, proteomics, molecular biology, grant writing, teaching and research.
He has a Cum Laude PhD in Public Health Genomics (Maastricht University), a Professional Doctorate in Engineering in Bioproduct Design (Delft University of Technology), did his Master’s degree in Life Science & Technology with a specialization in cell diagnostics (Delft University of Technology) and did his Bachelor’s degree (B.Tech, gold medal) in Biotechnology with a specialization in genetic engineering (Allahabad Agricultural Institute-Deemed University, India).
Applied translational skills:
Public Health Genomics, Biotechnology, Techno-economic Evaluation, Entrepreneurship, Grant Writing, License Negotiations, Contract Negotiations, Shares Purchase Agreement, Material Transfer Agreements, Hiring, Market Research, SWOT Analysis, Valorization, Patent Analysis, Project Management, Product Design & Innovation, Business Development, Corporate Finance, Tax Compliance, Translational Research, Technology Transfer, Health Policy, Healthcare Systems, Administration, Policy Advise on European Level.
Affymetrix mtDNA chips, Nano-LC-MALDI/MS (Liquid Chromatography-Matrix Assisted Laser Desorption/Ionization Mass Spectrometry), Yeast Two-Hybrid System, Flourescence Microscopy, Electrospray, PCR (Polymerase Chain Reaction), Molecular Cloning, Plasmid Vector Construction, Nano-Spectrophotometry, SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis), Western Blotting, β-Gal Assay, Agarose Gel Electrophoresis, Transformation, Plasmid, Genomic & Crude DNA Isolation Techniques, Chromosome counting, rDNA Technology, Cell Cultures, Basic Bioinformatics and other basic molecular biology techniques.
LIST OF FORMER PROJECTS PREVIOUSLY INVOLVED IN:
RAIL: non-invasive stratification of tumour heterogeneity for personalised cancer therapy
This is a € 2.4 million EU Horizon 2020 grant (2015-2019). The breakthrough technology, called “Radiomics”, which was recently published in Nature Communications, enables patient stratification through the use of imaging biomarkers acquired from routine CT & PET imaging. In Radiomics for lung cancer (RAIL) we validate and qualify a multi-site level I imaging biomarker together with a ready-to-use application to deliver more accurate prognostic information, personalise treatment for non-small cell lung cancer patients, reduce healthcare costs by EUR 500+ million and enable efficient clinical trial design
Mitochondrial genetics for the prediction of radiotherapy-induced lung toxicity risk: a prospective multicenter and mechanistic study
This is a € 572,500 Euros Dutch grant from the Dutch Cancer Society (KWF) to do research on “mitochondrial genetics for the prediction of radiotherapy-induced lung toxicity risk: a prospective multicenter and mechanistic study”. This study involves a large cohort of patients for establishing mitochondrial biomarkers to assess adverse effects induced in the irradiation.
Efficient integration of genome-based technologies into the health care system
Awarded as the APOGEE-Net/CanGeneTest Network pilot project from the APOGEE- Net/CanGeneTest Research and Knowledge Network on Genetic Services and Policy, Canada with a duration from 2011-2015. APOGEE-Net/CanGeneTest was formed in 2009 with a 5 year funding from CIHRs Institute of Genetics and Institute of Health Services and Policy Research. The general objective of the research and knowledge network is to streamline the technology transfer of clinically useful and cost effective genetic innovations towards the health care systems and support the development of evidence informed health policy.
Platform for sharing best practices for management of rare diseases (RARE-Bestpractices)
This is an EU framework program 7 grant planned as a 4-years project (2013-2016) that will develop a sustainable global networking platform, supporting the collection of standardized and validated data and the exchange of knowledge and reliable information among a multiplicity of countries. Its main goal is to improve clinical management of rare disease patients and narrow the existing gap in quality of health care among EU Member States as well as in other countries, by collecting, evaluating and disseminating best practices and sharing knowledge globally also considering the application of patients’ rights in cross-border healthcare EU Directive 2011/24.
An integrated European Platform for Pancreas Cancer Research: From Basic Science to Clinical and Public Health Interventions for a rare disease
This is a COST (European Cooperation in Science and Technology) EU framework program 7 grant (2013-2016) that proposes the creation of a unique European platform to facilitate the collaboration of a broad range of European and international PDAC (rare and dreadful diseases like pancreas cancer) multidisciplinary research groups to integrate knowledge and experience in a multidisciplinary way “from cell to society”; promote the application of uniform study tools and protocols; foster their optimal use by early-stage researchers; enhance the mobility and training of researchers; and permeate the society with the results originated by the Action. This Action will develop novel interdisciplinary tools that will improve our understanding of PDAC and its control by answering questions related to the aetiology, early detection and evidence-based and personalized treatment to enhance primary, secondary, an tertiary prevention, respectively, as well as on health management.
Increasing innovation potential by European-African Cooperation (InnXchange)
This is an EU framework program 7 planned as a 2 years project. The project aims to develop guidelines on innovation creation and innovation management, more specifically on how to identify research problems with real-world relevance, identify innovative solutions to those problems, evaluate the potential of ideas in terms of technical innovation, evaluate the potential of the ideas in terms of market demand and commercialization, consider the relevance of IPR and convert an innovation into a commercial product. This project has a duration of 2 years (2014-2016) and includes partners from South Africa, Kenya, Germany and the Netherlands.
Personalized medicine is on of the most innovative areas in the future of health research. However, today the full potential cannot be developed due to fragmented activities, insufficient communication and lack of generic solutions in the different areas. Therefore, the implementation of personalized medicine is a major challenge for Europe. The coordination and support action (CSA) PerMed (Personalized Medicine) was initiated to step up coordination efforts between European key stakeholders to allow synergies and avoid duplication or competition, to ensure maximum transparency and openness. PerMed aims to complement existing activities by identifying and promoting promising research topics, develop strategic research and innovation agendas in Europe and beyond and to bring forward the implementation of personalized medicine for the benefit of society.
Information and Communication Technology Future of Medicine (ITFoM)
This was an EU framework program (FP7) Flagship Pilot Project (duration 2011-2012). ITFoM wished to harness the vast potential of ICT to revolutionize human health care. The idea is to exploit the unprecedented amounts of detailed biological data for individual people, and turn this information into actual knowledge that helps us in taking medical and lifestyle decisions. By integrating the available biological data the aim is to construct computational models of the biological processes that occur in every human. Since everybody is different, the models will be tailored to each individual to reflect their own unique anatomical, physiological and genetic makeup. Our role is to ensure the smooth transition from the lab to healthcare systems by the time the technology is ready.
Ex-post evaluation of the health theme in framework program 7 – case studies
This is an EU RTD Tender. The study is expected to analyze the appropriateness and impact of the NMP-FP7 program, regarding the European societal and economic policies and needs. It shall analyze the objectives of the NMP-FP7 program, its implementation and execution, the outcome and impact of projects, and the efficiency of the program. It is supposed to develop recommendations for future European funding policy in the fields covered by the NMP program. Our focus here is on personalized medicine and medical technologies.
Public Health Genomics European Network (PHGEN II)
PHGEN II project was supported by a grant from the European Commission (2009-2012) with DG SANCO EU-Project No. 20081302. PHGEN II fulfils priority action 18.104.22.168 of WP 2008 by producing the first edition of “European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies”. It builds on the experiences of PHGEN I (Public Health Genomics European Network) which was a networking exercise to develop a common understanding of Public Health Genomics between all stakeholders in Europe and which identified the need for European coherent guidelines in that field. The consortium had over 22 partners.
Barriers and Access to Personalized Medicine in EU
This project developed several surveys for multi-stakeholders on personalized medicine to identify risks, barriers and access to personalized medicine in the EU with the overall objective to develop an EU personalized medicine index. The project was granted through the European Alliance for Personalised Medicine (EAPM).
Workshop on the Learning-Adapting-Leveling model
This workshop was developed and executed to help stakeholders understand the multi- faceted translational research pipeline, its bottlenecks, and potential solutions to resolve the bottlenecks. Stakeholders came from across the EU which included industry, EC, HTA professionals, patient groups, etc. The workshop was organized at the European Alliance for Personalised Medicine (EAPM).
Valorization in Public Health Genomics: A Conceptual Development from Technology Transfer to Healthcare Integration, Maastricht University, Netherlands
Individual Design Project
On “Feasibility Studies and Design of Nanotitre Fill Plate Technology” in the Analytical Biotechnology Group at the department of Biotechnology, Delft University of Technology (TU Delft), Netherlands. This project was based around the TU Delft patent “method of the dosed application of a liquid onto a substrate”. (September 2008 - August 2009)
Group Design Project
Design of Polyhydroxyalkanoates (PHA)-based intermediate products from waste streams for clients DSM BV and Paques BV www.dsm.nl www.paques.nl. This was based on a TU Delft (Netherlands) patent. (January 2008 - August 2008)
Detailed Techno-economic evaluation of PHA-based products for market entry and feasibility, TU Delft Netherlands (June 2008 - August 2008)
Turning Technology into Business
Research, analysis and evaluation of the TU Delft patent ‘system and method for integration of renewable energy and fuel cell for the production of electricity and hydrogen’ for possible business development and implementation, Netherlands. (September 2007 - January 2008)
Master Thesis on “Agrobacterium-mediated transformation of eukaryotic cells: the use of the yeast Saccharomyces cerevisiae to study the role of chromosome remodeling in T-DNA integration” in the department of Molecular & Developmental Genetics at the Institute of Biology, Leiden University, the Netherlands. (January 2007 - August 2007)
Did literature study research on “Diabetes Type II and the Role of DNA Damage” for DNage BV, a biopharmaceutical company based in Leiden Netherlands. (September 2006 - December 2006)
Designed a “Biosensor for detecting amount of growth factors required for dosage on site to increase facture healing” and did market research along with colleagues with regard to “Synthetic osteoinductive calcium phosphate bone filler material” for Progentix, a Life Science company based in Bilthoven Netherlands. (May 2006 - August 2006)
Thesis on “PCR amplification and cloning of gene encoding ribosomal inactivating protein from Chenopodium (Chenopodium album)” , AAIDU India. (January 2005 - June 2005)
Lal JA, Schulte in den Baümen T, Morré SA, Brand A. Public Health and Valorization of Genome-based Technologies: A new model. Journal of Translational Medicine 2011, 9:207. 2012
Brand A., Lal JA. European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies – the 2012 Declaration of Rome. Drug Metabolism and Drug Interactions 2012, 27(3):177-182.
Lal JA, Malogajski J, Verweij SP, de Boer P, Ambrosino E, Brand A, Oudburg S, Morré SA. Chlamydia trachomatis infections and subfertility: opportunities to translate host pathogen genomic data into public health. Public Health Genomics 2013, 16:50-61.
Brand A, Lal J, Malats N, Gutierrez-Ibarluzea I. The Public Health Genomics European Network (PHGEN). The Newsletter of the British Society for Human Genetics 2013, 48, 53-55.
Lal JA. Addressing the backlog of genome-based technologies in healthcare. The Newsletter of the British Society for Human Genetics 2013, 48, 60-61.
Lal JA, Sudbrak R, Lehrach H, Brand A. Functional Dynamics: From Biological Complexity to Translation and Impact in Healthcare Systems. Journal of Computer Science and Systems Biology 2013, 6:88-92.
Lal JA, Morré SA, Brand A. The overarching framework of translation and integration: a casefor the LAL model. Personalized Medicine 2014, 11(1):41-62.
Taruscio D, Morciano C, Laricchiuta P, Mincarone P, Palazzo F, Leo CG, Sabina S, Guarino R, Auld J, Sejersen T, Gavhed D, Ritchie K, Hilton-Boon M, Manson J, Kanavos PG, Nicod E, Tordrup D, Angelis A, Cam YL, Ensini M, Senecat J, Filippini G, Minozzi S, Giovane CD, Schünemann H, Meerpohl JJ, Prediger B, Schell L, Stefanov R, Iskrov G, Miteva-Katrandzhieva T, Serrano-Aguilar P, Perestelo-Perez L, Trujillo-Martín MM, Pérez-Ramos J, Rivero-Santana A, Brand A, Lal J, van Kranen H, Bushby K, Atalaia A, Ramet J, Siderius L, Posada M, Abaitua- Borda I, Alonso Ferreira V, HensPérez V. RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases. Rare Diseases and Orphan Drugs 2014, 1(1):5-9.
Sejersen T, Giovane CD, Filippini G, Leo CG, Meerpohl JJ, Mincarone P, Minozzi S, Sabina S, Schünemann H, Senecat J, Taruscio D, Morciano C, Laricchiuta P, Auld J, Gavhed D, Ritchie K, Boon MH, Manson J, Kanavos PG, Tordrup D, Nicod E, Guarino R, Ensini M, Cam YL, Prediger B, Schell L, Miteva-Katrandzhieva T, Stefanov R, Iskrov G, Serrano-Aguilar P, Perestelo-Perez L, Trujillo-Martín MM, Rivero A, Brand A, van Kranen H, Lal J, Morre S, Bushby K, Atalala A, Siderius L, Ramet J, Posada M. Methodology for production of best practice guidelines for rare diseases. Rare Diseases and Orphan Drugs 2014, 1(1):10-19.
Leyens L, Horgan H, Lal JA, Steinhausen K, Satyamoorthy K, Brand A. Working towards personalization in medicine: main obstacles to reaching this vision from today’s perspective. Personalized Medicine 2014, 11(7):641-649.
Lambin P, Zindler J, Vanneste B, Van De Voorde L, Eekers D, Compter I, Panth K, Peerlings J, Larue R, Deist T, de Jong E, Even A, Reymen B, Lustberg T, van Soest J, Rekers N, Roelofs E, Carvalho S, Leijenaar R, van Gisbergen M, Zegers C, Jacobs M, Brouwers P, van Timmeren J, Jochems A, Lal JA, Yaromina A, Ramaekers B, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Dubois L, Dekker A, Boersma L, Hoebers F, Smits K, Berlanga A, Walsh S. Decision Support Systems for Personalized and Participative Radiation Oncology. Advanced Drug Delivery Reviews 2017, 109:131-153 (Accepted 6 January 2016, Available online 14 January 2016).
Published Conference Proceedings
Lal J. Valorization of genome-based technologies in public health. In proceedings of the 4th European Public Health Conference. European Journal of Public Health 2011, Vol. 21, Supplement 1. 10 November, Copenhagen.
Lal JA. Valorization of Genomics in Public Health. Biomedica Life Science Summit 2011, Eindhoven Netherlands.
Lal JA, Schulte in den Bäumen T, Morré SA, Brand A. Valorizing Genomics in Public Health. Genetica Retraite 2011, Kerkrade Netherlands. 2012
Vondeling H, Lal J, Douw Karla, Cassiman JJ, Brand A. Public Health Genomics and Health Technology Assessment. In proceeds of the 9th HTAi Annual Meeting. Gac Sanit. 2012, 26(Espec Congr 2):6.
Taruscio D, Morciano C, Laricchiuta P, Mincarone P, Palazzo F, Leo CG, Sabina S, Guarino R, Auld J, Sejersen T, Sejersen K, Kemp NM, Ritchie K, Hilton-Boon M, Manson J, Kanavos P, Nicod E, Angelis A, Turdrop D, Le Cam Y, Ensini M, Senecat J, Filippini G, Minozzi S, Del Giovane C, Schünemann H, Meerpohl JJ, Stefanov R, Iskrov G, Miteva-Katrandzhieva T, Serrano-Aguilar P, Perestelo-Perez L, Trujillo-Martín MM, Pérez-Ramos J, Rivero-Santana A, Brand A, Lal JA, van Kranen HS, Bushby K, Ramet J, Siderius E, Posada M, Abaitua-Borda I, Hens- Pérez M, Alonso-Ferreira V. An overview of the RARE-Bestpractices project. In the Proceedings from the VIII international conference on rare diseases and orphan drugs (ICORD). St. Petersburg (Russia), Oct.31-Nov.2 2013. Rare Diseases and Orphan Drugs, February 2014, Volume 1 – Number 1, Supplement 1, page 14.
Conferences Attended (*invited presentation/lecture, **poster presentation)
Conferences Organized (*presentation)
Current teaching certifications:
This certification qualifies me to teach in any university in the Netherlands.
ACADEMIC YEAR 2008-2009, DELFT UNIVERSITY OF TECHNOLOGY, NETHERLANDS
ACADEMIC YEAR 2011-2012, MAASTRICHT UNIVERSITY, NETHERLANDS
ACADEMIC YEAR 2012-2013, MAASTRICHT UNIVERSITY
ACADEMIC YEAR 2013-2014, MAASTRICHT UNIVERSITY
ACADEMIC YEAR 2014-2015, MAASTRICHT UNIVERSITY
ACADEMIC YEAR 2016-2017 (SEMESTER JULY-DECEMBER), SHIATS India